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A B S T R A C TObjectives: Hospital admissions for exacerbations of chronic obstruc-
tive pulmonary disease are the main cost drivers of the disease. An
alternative is to treat suitable patients at home instead of in the
hospital. This article reports on the cost-effectiveness and cost-utility
of early assisted discharge in The Netherlands. Methods: In the
multicenter randomized controlled Assessment of GOing Home under
Early Assisted Discharge trial (n ¼ 139), one group received 7 days of
inpatient hospital treatment (HOSP) and one group was discharged
after 3 days and treated at home by community nurses for 4 days.
Health care resource use, productivity losses, and informal care were
recorded in cost questionnaires. Microcosting was performed for
inpatient day costs. Results: Seven days after admission, mean
change from baseline Clinical Chronic Obstructive Pulmonary Disease
Questionnaire score was better for HOSP, but not statistically signifi-
cantly: 0.29 (95% confidence interval [CI] 0.04 to 0.61). The difference
in the probability of having a clinically relevant improvement was
significant in favor of HOSP: 19.0%-point (95% CI 0.5%–36.3%). After 3see front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.010
@bmg.eur.nl.
ondence to: Lucas M.A. Goossens, Institute for Me
, The Netherlands.months of follow-up, differences in effectiveness had almost disap-
peared. The difference in quality-adjusted life-years was 0.0054 (95%
CI 0.021 to 0.0095). From a health care perspective, early assisted
discharge was cost saving: h244 (treatment phase, 95% CI h315
to h168) and h168 (3 months, 95% CI h1253 to h922). Societal
perspective: h65 (treatment phase, 95% CI h152 to h25) and h908
(3 months, 95% CI h553 to h2296). The savings per quality-adjusted
life-year lost were h31,111 from a health care perspective. From a
societal perspective, HOSP was dominant. Conclusions: No clear
evidence was found to conclude that either treatment was more
effective or less costly.
Keywords: COPD exacerbations, cost-effectiveness, early assisted
discharge, hospital-at-home.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hospital admissions for exacerbations of chronic obstructive
pulmonary disease (COPD) are important drivers of the high
treatment costs for the disease [1–5]. These admissions put great
pressure on scarce hospital beds of respiratory wards, especially
during winter months [6]. From an economic and organizational
point of view, it may be attractive to treat suitable patients at
home instead of in the hospital, if this is medically possible and
responsible.
Treatment schemes in which patients are treated and super-
vised at home, as an alternative to usual hospital treatment, are
often called hospital-at-home [7,8]. These schemes may either
avoid admission completely or discharge patients from the
hospital early and continue treatment at home.
Studies on the costs and cost-effectiveness of hospital-at-home
services for patients with a COPD exacerbation have shown varying
results. Shepperd et al. [9] concluded that a particular scheme inEngland led to significantly higher costs, whereas Skwarska et al. [10]
found cost savings in a different scheme in the same country.
Significant cost savings were reported for hospital-at-home services
in Australia [3], Spain [11,12], and the United States [13]. The results
of an Italian study were inconclusive [14].
Although these studies were performed in different countries
and in different health care systems, they had some aspects in
common. First, they all took a health care perspective; the costs
or value of resources used outside of the health care sector were
not taken into account. Second, the length of treatment was
variable in each study. Physicians and/or nurses decided on the
timing of discharge from the hospital or from treatment at home,
depending on the patient’s recovery.
The current article reports on the cost-effectiveness and cost-
utility of an early discharge scheme that is different in the two
aspects mentioned above. The study was performed in The
Netherlands as part of the Assessment of GOing Home under
Early Assisted Discharge trial. In this multicenter randomizedSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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inpatient hospital treatment for 7 days. The other group was
discharged after 3 days and was treated and supervised at home
for the remaining 4 days. The Netherlands has a nationwide
infrastructure for community nursing provided by homecare
organizations. Dutch hospitals do not deliver health care in the
community. Therefore, the care at home in this trial was provided
by community-based homecare organizations that mostly employ
generically trained nurses and few specialized nurses. The clinical
results of this study have been presented in detail elsewhere [15].Methods
Study Design
The Assessment of GOing Home under Early Assisted Discharge
study was a randomized, controlled, multicenter trial comparing
two management strategies for patients admitted to the hospital
for a COPD exacerbation [16]. After 3 days of usual hospital
treatment, patients were randomized to be either discharged
home with homecare or continue hospital treatment. The total
duration of this initial treatment phase was 7 days for both
groups, unless the treatment failed and patients had to be either
readmitted or had to prolong their hospital stay. Patients were
followed for 3 months, with outcome measurements scheduled
after 7 days and 3 months.
Patients
Patients admitted to one of the participating hospitals because of
an exacerbation of their COPD were screened for eligibility. On
the day of admission, they were considered potentially eligible
for early discharge if they met the following inclusion criteria:
age 40 years or older, sufficiently competent to consider informed
consent, and a smoking history of 10 or more pack-years. To be
randomized on day 3 of the admission, their physical and
respiratory complaints (dyspnea, wheezing, and rhonchi) had to
be improved compared with those on the day of admission, they
should not be depending on therapies that could not be admin-
istered at home, and they should be able to visit the toilet
independently. Also, the blood sugar level had to be normal or
only moderately increased (r15 mmol/l or regulated independ-
ently at home).
Exclusion criteria were major uncontrolled comorbidity, men-
tal disability, active alcohol or drug abuse, inability to understand
the program, living outside the region of the participating home-
care organization, indication for admission to the intensive care
unit or noninvasive ventilation, and insufficient availability of
informal care at home.
Intervention
During the first 3 days of the treatment, all patients received
usual hospital care. The pharmacological part of this treatment
consisted of systemic corticosteroids (10 days), nebulized bron-
chodilators, subcutaneous thrombosis prophylaxis, and stomach
protection. If necessary, oxygen therapy and/or antibiotics were
prescribed. Nonpharmacologic usual care consisted of physio-
therapy for all patients for breathing and coughing instructions
and dietary advice if indicated (body mass index r 21 or 10%
unintended weight loss in the 6 months prior to admission).
Patients randomized to early assisted discharge were dis-
charged home on the fourth day of admission and further treated
at home. Community nurses visited the patient once to three
times on the day of discharge and the three following days. The
main objective of the supervision of the home treatment was the
observation of the patient’s recovery and providing counselingand reassurance to the patient and the primary informal care-
giver. The nurses also addressed medication compliance and
inhalation techniques, provided support in applying breathing
and coughing techniques, and, if applicable, in adhering to
dietary advice. If necessary, patients could be supported in their
daily life activities (e.g., washing and dressing) by the home care
organization. During the 4 days of home treatment, the emphasis
was on the recovery of the exacerbation. In case COPD symptoms
suddenly worsened, the patients could contact the respiratory
hospital ward directly and round the clock. The general practi-
tioner was informed of the early discharge, but the respiratory
physician of the hospital kept the final responsibility.
Effects
The following outcome measures were used: 1) the incremental
change from day of randomization in Clinical COPD Question-
naire (CCQ) score at day 7 and 3 months; 2) the incremental
proportion of patients with a clinically relevant improvement in
the CCQ score (i.e.,Z0.4 units) [17] on day 7 and at 3 months; and
3) the gain in quality-adjusted life-years (QALYs) after 3 months
using utilities as measured by the EuroQol five-dimensional (EQ-
5D) questionnaire using the Dutch tariff for the valuation of
health states [18]. The CCQ score can range from 0 (best possible
score) to 6 (worst possible score). Based on the Dutch tariff, the
EQ-5D questionnaire score can range from 0.329 (worst possible
utility) to 1 (perfect health).
Costs
Costs were calculated from two perspectives, the health care
perspective and the societal perspective. The former included
only the direct health care costs within 3 months after random-
ization. The latter includes direct health care costs, non–health
care costs, and costs of productivity loss for the 3-month follow-
up period. This is in accordance with the Dutch recommenda-
tions that economic evaluations should be conducted from a
societal perspective [19].
In the 7-day treatment phase, the duration of hospital admis-
sion and the amount of community nursing care were recorded.
Patients randomized to early discharge were asked to record all
additional formal health care as well as informal care and days of
absence from paid work of the informal caregiver in a 4-day cost
diary, a specially designed questionnaire on the amount of
resources used on each day.
During the follow-up phase, the following types of resource
use were recorded on a weekly basis in costs questionnaires that
were distributed for each month of the trial: number and length
of hospital readmissions, number of visits to the emergency
department, number of contacts with pulmonologist and other
specialist physicians, general practitioner, respiratory nurse,
homecare, dietician, physiotherapist, and social worker, number
of ambulance rides, and medication use. Direct non–health care
costs recorded in these questionnaires were paid and unpaid
domestic help, including the time spent by the primary informal
caregiver. To capture all informal care, respondents were asked to
provide information on help with domestic tasks, personal care,
and practical support. They were instructed to consider only the
time that they would not have spent on these purposes if the
patient had not experienced the exacerbation. Indirect costs were
costs of productivity losses. The days a patient was absent from
paid work were recorded in the cost questionnaires.
Costs (in 2009 euros) were calculated by multiplying the
volume of resource use (such as hospital days, physician visits,
time spent by formal and informal caregivers, and production
losses) by a cost per unit that includes total, not marginal, costs.
Except for inpatient hospital days, standard unit costs from the
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care resource use. The unit costs for production losses repre-
sented the mean of sex-specific mean wages per day, weighted
for the sex distribution in our sample.
Unit costs are presented in Table 1. Medication prices were
based on the official list prices of drugs obtained from retail
pharmacists published on the Internet [21], including value
added tax and increased by a standard prescription reimburse-
ment for the pharmacist. Costing for permanent medication was
done on the basis of one prescription per 3 months.Costs of Inpatient Hospital Days
Costs for each inpatient hospital day were estimated by using the
microcosting methodology, which provides cost estimates that
most accurately reflect actual costs by identifying cost compo-
nents at the most detailed level [22,23].
We interviewed 10 nurses, 3 pulmonologists, and 1 laboratory
staff member who worked in one of the hospitals that partici-
pated in the trial. They were required to have been involved in
the treatment of at least three randomized patients in order to be
acquainted with the disease severity of these patients and of the
intensity of care that they needed.
First, during interviews with health care professionals partic-
ipating in the trial, all steps in the treatment and nursing process
were identified. Then, at the two hospitals that recruited the
most patients, which were the Catharina Hospital in Eindhoven
and Atrium Medical Centre in Heerlen, pulmonologists, resi-
dents, nurses, and laboratory staff who participated in the trial
and were very familiar with the type of patients with COPD
enrolled were asked to provide best estimates of resource
utilization. Separate estimates were made for each inpatient
hospital day to detect possible changes in care intensity over
the course of the stay. Using standardized reporting templates,
the participants were asked how many minutes they spent on
each component of care per average patient. In addition, nurses
were asked what proportion of their yearly working hours were
‘‘indirect treatment time,’’ that is, time not spent directly caring
for patients, but, for instance, on trainings and department
meetings. Indirect treatment time was then allocated to patients
by adding a markup of 24.5% to the amount of direct treatmentTable 1 – Unit costs (euros 2009) [20].
Type of resource Unit costs (h)
GP, consultation 28
GP, home visit 43
GP, phone call 14
Specialist, consultation 64
Specialist (h) 135.50
Resident (h) 27.85
Nurse in hospital (h) 26.75
Physiotherapist, consult 36
Dietician, consult 27
Pulmonary nurse, consult 36
Social worker 36
Emergency room, visit 151
Ambulance transport 504
Community nurse (h) 65
Domestic community care, per hour 24
Informal care (h) 12.5
Production loss (h) (patient) 29.72
Inpatient hospital day, standard price 435
GP, general practitioner.time they received. This markup was calculated as the proportion
of time spent on indirect treatment (averaged over all nurses),
divided by the proportion of time spent on direct treatment
(averaged over all nurses) [23].
Labor time was valued by using standardized costs per minute,
which reflected national average incomes per profession (including
social premiums, fees for irregular working hours, and the costs of
replacement during illness) divided by the number of workable
minutes per year. For consulting physicians, the standardized
time-costs included a 43% markup for indirect treatment time.
For residents, a markup of 30% was applied. The latter percentage
was chosen to be in between those for physicians and nurses.
For hotel and nutrition costs, the national reference costs
from the Dutch Manual for Costing Studies were used. For the
first and last day of hospital admission, only half of these costs
were taken into account. Finally, labor and hotel costs for each
hospital day were supplemented with a proportional markup for
overhead and capital costs (42%), which was the national refer-
ence percentage [20]. In these cost calculations, the day of
admission was considered as day 1 when patients were admitted
before 12:00 pm. If the patient was admitted after 12 pm, the day
of admission was considered day 0 and the following day as day
1. Hence, costs of day 1 were calculated separately for patients
who were admitted on day 1 and for patients who were admitted
on day 0. For inpatient day 4, separate calculations were
performed for the patients who were discharged and those who
remained in hospital.
Statistical Analysis
Effects
The change from day of randomization in the CCQ score and the
EQ-5D questionnaire score was analyzed in repeated-measures
analyses. In these linear models with correlated errors, the
covariance matrix was unstructured.
The final model was developed in a backward selection
process. In addition to time (i.e., measurement at day 7 [end of
treatment] or at the end of follow-up) and the interaction of time
and treatment, the starting model contained the following
variables: baseline CCQ or EQ-5D questionnaire score, treatment
center, age, gender, comorbidity, smoking status, living situation,
availability of informal caregiver, presence of homecare prior to
admission, and course of oral corticosteroids and/or antibiotics
prior to admission. In each step, the variable with the highest P
value was removed unless its exclusion led to a 10% change in
the estimated treatment effect [24].
The explanatory variables in the final model were treatment,
the CCQ score or the EQ-5D questionnaire score on the day of
randomization, time (moment of measurement), the interaction
of treatment and time, and Charlson’s comorbidity score (1
or41, only in the EQ-5D questionnaire model) [25].
In the CCQ model, the coefficient for treatment could directly
be interpreted as the marginal difference in change from the day
of randomization to day 7, that is, the difference between the
hypothetical situations in which all patients were treated at
home or all received usual hospital treatment. The marginal
difference in change from the day of randomization at 3 months
was the sum of the coefficient for treatment and the coefficient
for the interaction of treatment and measurement.
To calculate the mean marginal difference in the EQ-5D
questionnaire score per measurement, scores were predicted
for all patients for each measurement: one score for each treat-
ment. To calculate QALYs, the mean utility of two subsequent
measurements was multiplied with the number of days between
these measurements, the sum of which was divided by 365.25.
The probability of experiencing an improvement of 0.4 or
more units in the CCQ score between the day of randomization
Table 2 – Baseline characteristics.
Usual
hospital
care (n ¼ 69)
Early assisted
discharge
(n ¼ 70)
Age (y), mean  SD 67.80  11.30 68.31  10.34
Males (%) 55.1 68.9
Current smoker (%) 39.1 32.9
Pack-years, mean  SD 44.52  31.04 46.97  27.27
Body mass index,
mean  SD
25.57  4.33 24.97  5.14
Receiving homecare
before admission (%)
23.2 24.3
Charlson comorbidity
score, mean  SD
1.68  1.10 1.74  1.10
Score4 1 (%) 39.1 45.7
CCQ score , mean  SD 2.22  0.97 2.63  1.03
EQ-5D questionnaire
score, mean  SD
0.71  0.22 0.66  0.26
CCQ, Clinical Chronic Obstructive Pulmonary Disease Question-
naire; EQ-5D, EuroQol five-dimensional.
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analyses. Explanatory variables were treatment and the CCQ
score on the day of randomization. The results of these regres-
sion analyses were used to predict the probabilities in each
treatment group, based on the CCQ score distribution of the full
sample (two treatment groups combined).
Costs
In the usual care group, total costs during the 7-day treatment
phase include all hospital costs. In the early discharge group,
these costs were calculated as the sum of the hospital costs, the
community care costs, and the costs of health care utilization as
recorded in the diaries for the 4-day period of homecare.
Total costs during the follow-up phase were calculated as the
sum of the predicted monthly treatment costs, the predicted
medication costs, and the costs of readmissions. To obtain the
predicted costs, the monthly cost questionnaires were analyzed
in a linear repeated-measures model with correlated error terms
and unstructured covariance. The dependent variable was the
costs in a certain month. The explanatory variables were the time
(first, second, or third month) and the interaction of treatment
and time of measurement. The results were used to predict the
mean costs per treatment group for each month. Monthly
medication costs were analyzed in the same way. Because all
explanatory variables were dummy variables, it was not neces-
sary to apply a transformation to the cost variable to achieve a
normal distribution. A generalized estimating equations model,
which could have been used for that purpose, would have led to
the same results as the linear repeated-measures model with
correlated error terms. The reason for choosing the latter model
is its more intuitive interpretation and the analogy with the
effects models.
Intention to Treat
Data analysis was performed according to the intention-to-treat
principle. Data from patients who died, quit participation, or
were otherwise lost to follow-up were included in the analysis up
to the point of dropout.
Missing data were handled by the repeated-measures models,
which have the capacity to exploit the covariance structure of
the existing data to adjust the results. This characteristic of the
statistical models was used to achieve unbiased estimates of the
treatment effect at each measurement and of the mean costs for
each month during follow-up [26,27].
Cost-Effectiveness and Cost-Utility
Health outcomes on day 7 were related to costs of the initial
treatment phase; health outcomes after 3 months were related to
total costs of the initial treatment phase and the follow-up period
combined. If one of the treatment options was more effective and
also more costly, results were presented in incremental cost-
effectiveness ratios (ICERs)—the additional cost per additional
unit of health gain or the savings per unit of health loss—which
was calculated as the difference in mean costs divided by the
difference in mean health outcomes.
Uncertainty around the estimates of costs and health out-
comes was addressed by bootstrapping the data [28]. All statis-
tical analyses were performed on each of 1000 bootstrap
replications. The mean values of incremental costs and effects
from the bootstrap replications were used as the point estimates.
The 95% confidence interval around the difference in mean total
costs and health outcomes was determined by taking the 2.5th
percentile and the 97.5th percentile of these bootstrap replica-
tions. The bootstrap replicates for the outcomes and costs after 3
months were plotted in cost-effectiveness planes (CE planes) [29].The information from the CE planes on incremental costs per
QALY was summarized in cost-effectiveness acceptability curves,
which represent the likelihood that early assisted discharge is the
most cost-effective option at different values of the maximum
acceptable willingness to pay for a health outcome [30].
Sensitivity Analyses
Several sensitivity analyses were performed. First, the costs of
informal care in the follow-up period were left out of the total
costs in the societal perspective (SA1). Second, a different unit
cost per inpatient hospital day was used instead of the costs from
the microcosting study (SA2). This cost was the standard unit
price from the Dutch Manual for Costing Studies [20], which is
based on a broad spectrum of diagnoses and is constant for all
days during an admission.
In addition, to express the uncertainty about the estimate of
the costs per inpatient hospital day, sensitivity analyses were
performed by using the estimates of the respondent with the
highest (SA3) and lowest (SA4) costs (most costly and least costly
health care provider) and the highest (SA5) and lowest (SA6)
estimates of all aspects of care across respondents (most costly
and least costly scenarios).Results
Patients
From December 2007 to March 2011, 139 patients were random-
ized. In the usual care group, 75% of the patients completed the
entire trial. In the hospital-at-home group, 90% remained in the
trial until the end of the follow-up period. Because of early
dropout or failure to complete questionnaires, no effectiveness
data were available for 1% of the patients and no cost data for
12%. The characteristics of all randomized patients are presented
in Table 2.
Costs of Inpatient Hospital Days
Table 3 shows that the first day of the hospital admission was the
most costly. After that, the intensity of care by physicians and
Table 3 – Costs per inpatient hospital day.
Day Usual hospital care (h) Early assisted discharge (h) Difference (h)
0 (with admission after noon) 319 319 –
1 (with admission before noon) 323 323 –
1 (for patients admitted on day 0) 195 195 –
2 192 192 –
3 178 178 –
4 162 188 –
5 157 –
6 156 –
7 167 –
Total costs for admission 1430 976 454
SA2y 3045 1305 1740
SA3y 1721 1122 599
SA4y 1228 858 370
SA5y 2312 1534 778
SA6y 952 655 297
 Totals are based on the assumption that 50% of the patients are admitted on day 0 and 50% on day 1. This does not affect the difference
between the treatment arms, because the same assumption is made for both groups.
y SA2 (sensitivity analysis 2): standard costs per inpatient hospital day instead of costs from the microcosting study. SA3/4: cost estimates
from most and least costly health care provider in the microcosting study. SA5/6: highest and lowest estimates of care costs across
respondents.
Table 4 – Cost-effectiveness of early assisted discharge versus usual inpatient hospital care.
Usual hospital
care
Early assisted
discharge
Difference
Effects
Mean change in the CCQ score, day 7 0.303 0.013 0.290 (0.03; 0.61)
Mean change in the CCQ score, end of follow-up 0.024 0.065 0.041 (0.41; 0.48)
Probability of improved CCQ score, day 7 51.3% 32.7% 19.41%
(36.25%; 0.50%)
Probability of improved CCQ score, end of follow-up 39.9% 35.8% 4.17% (21.94%;
15.27%)
QALYs 0.175 0.170 0.005 (0.021; 0.0095)
Health care perspective
Costs of initial episode (h) 1,463 1,219 244 (315; 168)
Costs of initial episode plus follow-up 4,297 4,129 168 (1,253; 922)
Incremental cost-effectiveness ratios (h)
Point deterioration in mean CCQ score, day 7 842
Point deterioration in mean CCQ score, end of follow-up 4,098
Additional patient without improved CCQ score, day 7 1,257
Additional patient without improved CCQ score, end of
follow-up
4,000
Incremental QALY lost 31,111
Societal perspective
Costs of initial episode (h) 1,463 1,398 65 (152; 25)
Costs of initial episode plus follow-up (h) 5,395 6,304 880 (580; 2,268)
Incremental cost-effectiveness ratios (h)
Point deterioration in mean CCQ score, day 7 224
Point deterioration in mean CCQ score, end of follow-up Usual hospital care is dominant
Additional patient without improved CCQ score, day 7 335
Additional patient without improved CCQ score, end of
follow-up
Usual hospital care is dominant
Incremental QALY lost Usual hospital care is dominant
CCQ, Clinical Chronic Obstructive Pulmonary Disease Questionnaire; QALY, quality-adjusted life-year.
Savings per unit of health lost.
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Table 5 – Resource use.
Usual hospital care Early assisted discharge Difference
Initial treatment phase
Community nursing (h) – 3.25 3.25
Informal care (h) – 13.03 13.03
GP, home visits – 0.015 0.015
Follow-up period
GP, consultations 0.76 0.86 0.11
GP, home visits 0.45 0.81 0.36
GP, phone calls 0.44 0.82 0.38
Pulmonologist, consultations 1.34 1.69 0.35
Other specialist, consultations 1.27 1.24 0.03
Paramedic care, consultations 3.88 8.88 5.01
Emergency room 0.35 0.32 0.04
Ambulance rides 0.16 0.05 0.11
Community nursing (h) 9.60 9.65 0.05
Domestic community care (h) 13.93 12.05 1.87
Readmissions 0.39 0.39 0
Informal care (h) 78.50 118.97 40.47
Production losses (h) (patient) 2.38 15.56 13.18
GP, general practitioner.
Table 6 – Treatment costs (in euros, 2009).
Usual hospital care (h)
Early assisted
discharge (h)
Difference (h)
Initial treatment phase
Inpatient days 1463 1001 462
Community nursing – 211 211
Other costs of home treatment (societal perspective) – 186 186
Other costs of home treatment (health care perspective) – 6 6
Total (health care perspective) 1463 1219 244 (315; 168)
Total (societal perspective) 1463 1398 65 (152; 25)
Follow-up period
GP 46 71 25
Pulmonologist 86 107 21
Specialist 114 99 15
Paramedic care 191 314 123
Emergency room 52 48 4
Ambulance 80 25 55
Medication 346 396 50
Community nursing 971 932 39
Readmissions 941 941 0
Informal care 973 1488 515
Production losses, patient 71 466 395
Totaly (health care perspective) 2834 2910 76 (1005; 1159)
Totaly (societal perspective) 3933 4906 973 (478; 2403)
Total study period (initial treatment phase plus follow up-period)
Health care perspectivey 4297 4129 168 (1253; 922)
Societal perspectivey 5395 6304 908 (552; 2296)
GP, general practitioner.
 These costs are higher than those given in Table 3 because the costs of prolonged hospital stay beyond 7 d (usual hospital care group) and
the costs of readmission during the initial treatment phase (usual hospital care group) were included.
y Totals for follow-up period are based on regression analysis; means per cost category are not.
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total inpatient hospital costs during the 7-day treatment phase
were h1430 for the usual hospital care group and h976 for the
early assisted discharge group.
Effects
The mean improvement in CCQ scores between days 3 and 7 was
larger in the hospital group than in the early assisted discharge
group (0.303 vs. 0.013), but this difference was of only border-
line significance (Table 4). Both groups showed an almost equal
improvement in the CCQ score between day 3 and 3 months.
There was a statistically significant difference between the
groups in the probability of having a clinically relevant improve-
ment in the CCQ score between days 3 and 7 (51.3% in the usual
hospital care group vs. 31.7% in the early discharge group). It was
not significant between day 3 and 3 months (39.9% vs. 35.8%,
respectively).
The difference in QALYs was very small and not statistically
significant.
Resource Use and Costs
Resource use is presented in Table 5. Table 6 shows that the costs
for the first hospital admission were, obviously, lower in the early
assisted discharge group than in the usual hospital care group.
Hospital costs were reduced by h462 per patient. These savings
were partly offset by the costs of community nursing care, which
were h211, resulting in a net cost reduction of h244. During the
follow-up phase, the early discharge group had somewhat higher
costs than the usual hospital care group. In total, from a health
care perspective, early assisted discharge led to mean cost
savings of h168 (95% confidence interval h1253 to h922) per
patient.
From a societal perspective, savings in hospital costs during
the 7-day treatment phase were offset not only by the costs of
community nursing but also by the costs of informal care and
production losses. From this perspective, the initial treatment
phase was only h65 less costly in the early discharge group.
Including the costs during the follow-up phase, which were h945
higher in the early discharge group, led to a total estimated cost
increase of h880 (95% confidence interval h580 to h2268) per
patient in the early discharge group, from a societal perspective.
This is primarily due to the higher costs of informal care and the
greater productivity loss (Table 6).
Cost-Effectiveness
From a health care perspective, all point-estimates of costs and
effects pointed toward lower costs but somewhat less effects for
early assisted discharge. Therefore, the ICERs of early assisted
discharge versus usual hospital care represent cost savings per
unit of health forgone. After 7 days, the savings per unit of
deterioration in the CCQ score were h842; at 3 months, this ratio
was h4098 (see Table 4). The savings per additional patient
without a clinically relevant improvement in the CCQ score were
h1257 after 7 days and h4000 at 3 months. The savings per QALY
lost were h31,111. The probability that early assisted discharge
was cost saving from a health care perspective was 61.2%.
From the societal perspective, no ICERs were calculated for
the outcomes after the follow-up period because the point-
estimates of costs and effects pointed toward dominance of the
usual hospital care group. The probability that early assisted
discharge was cost saving was 12% from this perspective. After 7
days, the savings per unit deterioration in the CCQ score were
h224. The savings per patient without a clinically relevant
improvement in the CCQ score were h335.There is considerable uncertainty around incremental costs
and effects, as is presented in CE planes, for both perspectives
(Fig. 1). From the health care perspective, there is a greater
probability that early assisted discharge leads to net cost saving
than from the societal perspective, as is shown by a greater
proportion of combinations of incremental costs and effects
below the x-axis. When adopting the health care perspective,
the largest proportion of all dots was located in the southwest
quadrant, with lower costs and less optimal health outcomes for
early assisted discharge. From the societal perspective, the
majority of simulated outcomes were found in the northwest
quadrant, with higher costs and less optimal health outcomes for
early assisted discharge.
The cost-effectiveness acceptability curves in Figures 2 and 3
show that, from a health care perspective, early assisted
discharge is likely to be cost-effective for thresholds up to
h46,000. From a societal perspective, early assisted discharge
is unlikely to be considered cost-effective compared with usual
hospital care at any threshold of maximum costs per QALY
gained. In the base case, this probability is close to 10% for all
thresholds.
Sensitivity Analyses
Table 7 shows the results of the sensitivity analyses. The ICERs
for usual hospital care compared with those for early assisted
discharge were sensitive to changes in the assumptions. In the
initial treatment phase, early assisted discharge was almost
certain to lead to cost savings from a health care perspective,
under any of the alternative assumptions about the costs of
inpatient hospital days, similar to the base-case analysis. From a
societal perspective, costs savings were very likely to occur
during the initial treatment phase, except if mean costs per
hospital day were assumed to be much lower than in the base-
case analysis (SA4 and SA6).
Over the entire 3-month period, cost savings were more
likely to occur than cost increases from a health care perspective.
This likelihood was more or less comparable across sensitivity
analyses, except when the standard unit costs for inpatient
hospital days were applied (SA2). In this sensitivity analysis, the
likelihood that early assisted discharge led to cost savings was
99.8%
From a societal perspective, cost savings were unlikely to
occur under all assumptions except when the standard unit costs
for inpatient hospital days were used (SA2). This is the only
sensitivity analysis in which early assisted discharge was not
dominated by usual hospital care.
The cost-effectiveness acceptability curves shown in Figures 2
and 3 make it clear that assumptions on the costs of inpatients
days do not have a strong impact on the probability that early
assisted discharge is to be cost-effective.Discussion
This study compared the costs and health effects of two treat-
ments for patients who were admitted to the hospital with a
COPD exacerbation. Patients stayed in the hospital for 7 days, or
went home after 3 days where they were supervised and treated
by community nurses. No clear evidence was found to conclude
that either treatment was more effective or less costly than
the other.
Against the obvious savings in inpatient hospital costs, there
were extra costs for community nursing, and, from a societal
perspective, informal care. While costs from a societal perspec-
tive were higher among patients who were discharged early, this
difference was not statistically significant. Cost savings in the
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Fig. 1 – CE planes. Health care perspective, incremental costs set against (a) incremental improvement in the CCQ score, month
3; (b) incremental proportion of patients with clinically relevant improvement, month 3; and (c) incremental QALYs. Societal
perspective, incremental costs set against (d) incremental improvement in the CCQ score, month 3; (e) incremental proportion
of patients with clinically relevant improvement, month 3; and (f) incremental QALYs. CCQ, Clinical Chronic Obstructive
Pulmonary Disease Questionnaire; CE, cost-effectiveness; QALY, quality-adjusted life-year.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 1 7 – 5 2 8524health care perspective were not significant either. However,
early discharge was much more likely to reduce health care costs
than it was to reduce total societal costs.
At the end of the 7-day treatment phase, all outcomemeasures
had improved more in the patients in the usual hospital treatment
group than in patients in the early discharge group. This differ-
ence, however, was not statistically significant, except for the
probability of having a clinically relevant improvement in the CCQ
score on day 7. Patients who underwent usual hospital care were
more likely to experience an improvement of more than 0.4 points
in the CCQ score. By the end of the follow-up period, at 3 months,
the difference had disappeared. In a publication of the clinical
results of this study, it was reported that there was no difference inreadmissions and mortality, while treatment failures were some-
what more frequent in the usual hospital care group [15].
From a societal perspective, no ICERs were calculated for
outcomes after the follow-up period because early assisted
discharge led to higher mean costs as well as less optimal health
outcomes: it was dominated by usual hospital treatment. This
was illustrated by the large proportion of bootstrap samples in
the northwest quadrant of the CE plane and by the low accept-
ability curves. The verdict of dominance is often fatal for the
conclusion on the treatment to which it is applied. In this case,
however, it might be given less weight, because the dominance is
based on a very small difference in effects. Analogously, it could
be argued that the position of the majority of bootstrap
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Fig. 2 – Health care perspective, cost-effectiveness acceptability curves for QALY gain/loss. SA2 (sensitivity analysis 2): stan-
dard costs per inpatient hospital day instead of costs from microcosting study. SA3/4 cost estimates from most and least
costly health care provider in microcosting study. SA5/6: highest and lowest estimates of care costs across respondents.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 1 7 – 5 2 8 525replications on the CE plane should not be described as the
northwestern quadrant of the CE plane, but rather as the
proximity of the y-axis and the origin.0%
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ting study. SA3/4 cost estimates from most and least costly
lowest estimates of care costs across respondents.
Table 7 – Sensitivity analyses.
Cost difference (EAD minus HOSP) (h) ICER Probability of cost savings for early discharge (%)
Health care costs, initial episode
Base case 244 100
SA2 1522 100
SA3 389 100
SA4 160 100
SA5 568 100
SA6 86 99.0
Societal costs, initial episode
Base case 65 93.2
SA1 65 93.2
SA2 1343 100
SA3 210 100
SA4 19 33.9
SA5 389 100
SA6 93 2.0
Health care costs, 3 mo
Base case 168 31,111 61.2
SA2 1464 271,111 99.8
SA3 313 57,963 69.2
SA4 84 15,556 55.1
SA5 492 91,111 81.2
SA6 10 1,852 50.0
Societal costs, 3 mo
Base case 880 Dominance 11.5
SA1 370 Dominance 25.4
SA2 416 77,037 69.9
SA3 735 Dominance 15.7
SA4 964 Dominance 9.8
SA5 556 Dominance 21.6
SA6 1038 Dominance 8.1
Notes. SA1 (sensitivity analysis 1): informal care costs during follow-up period not included in societal costs. SA2: standard costs per inpatient
hospital day instead of costs from the microcosting study. SA3/4: cost estimates from most and least costly health care provider in the
microcosting study. SA5/6: highest and lowest estimates of care costs across respondents.
EAD, early assisted discharge; HOSP, inpatient hospital treatment; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
 Cost savings per QALY lost.
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generally be considered cost-effective if the new treatment were
more effective than the comparator. In this case, however, the
threshold must represent the cost savings that would be required
to make a health loss acceptable (willingness to accept). There
are indications that this threshold is much higher than the
threshold for the amount of incremental costs that society would
be willing to pay for health gains [31]. In this light, the inter-
pretation of the acceptability curves could also shift somewhat in
favor of the comparator arm [32].
This is the first study to include the costs of informal care in
the costs of the early assisted discharge scheme. The impact of
this was considerable. In the 7-day treatment phase, the cost
savings for early assisted discharge decreased from h244 to h65
per patient. For the full treatment period, cost savings turned into
cost increases.
The costs of informal care during the follow-up phase were
much higher in the early assisted discharge group. We have no
good explanation for this finding. Although it might be a true
difference, it is also possible that informal caregivers in the early
assisted discharge group were more primed to record their
activities as informal care, because of the attention that it may
have got during the initial treatment phase at home. For this
reason, we performed a sensitivity analysis in which informal
care costs during the follow-up period were excluded from thecalculations. In this analysis, total costs for the early discharge
group were still higher, mostly because of the higher number of
patient workdays lost. The difference was smaller than in the
base case, as was the probability of a cost increase.
Generally, the amount of informal care can be recorded in two
ways: the diary method, in which resource use is recorded on a
daily basis, and the recall method, in which a respondent is asked
to provide information on the preceding week [33]. Both methods
have advantages and disadvantages. Most importantly for the
diary method, it may not be feasible to ask to complete it over a
longer period of time. However, the recall method has been shown
to have a potential to overestimate informal care time, when
respondents do not take into account that they have combined
certain activities with providing informal care [33]. The diary
method was applied during the treatment phase in our study,
while the follow-up period was covered by the recall method.
How to value informal care is still debated. Different estima-
tion methods have led to different estimates [34]. Following
Dutch guideline recommendations, we used a shadow price of
h12.50 per hour, which was based on the standard tariff for the
reimbursement of housecleaning costs for chronic patients.
When it is applied to informal care, it reflects the assumption
that informal caregivers cannot match the efficiency of profes-
sionals, who would require a higher hourly tariff. While our cost
estimates are dependent on the assumed hourly unit costs of
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 1 7 – 5 2 8 527informal care, the unit costs we have used are in the center of the
range of costs (h7–h17) that were estimated by Koopmanschap
et al. [34] using different valuation methods.
Like the costs of informal care, the productivity losses in the
early assisted discharge group were higher as well. This was
mostly due to one patient who incurred a very high amount
of costs.
In our study, the duration of hospital or home treatment was
fixed. Whenever possible, patients were discharged or homecare
was stopped after 7 days. It is conceivable that the threshold for
adding another day of treatment may be lower for treatment at
home. In other studies in which no fixed treatment duration was
used and physicians were fully free to decide on the duration of
treatment, different durations were observed for each treatment
group and the total duration of treatment in hospital-at-home
was longer than that in usual hospital care. Such an approach
may have commingled the effects of the treatment per se with
the effects of the length of stay or even with the timing of health
measurements. Treating patients for a longer time may lead to
better health, but measuring their health at a later time may also
lead to seemingly better results. Our design made it possible to
make the comparison exclusively on the basis of where and by
whom treatment was provided. Four patients in the usual
hospital care group remained in the hospital for a longer period
of time. One patient who was discharged early needed to be
readmitted within the 7 days of initial treatment. The additional
costs of these patients were included in the costs of the initial
treatment phase. No patient required homecare beyond 7 days.
It is possible—although far from certain—that the early
assisted discharge treatment would in daily practice be longer
than the hospital treatment. This would clearly lead to higher
costs than in this trial, whereas the study did not yield indica-
tions that it would or would not improve health outcomes.
The patients in the trial can be considered representative for
other patients who would be eligible and willing to participate in
a comparable program outside of a trial. Almost two thirds of
screened patients were too ill, did not have an obvious informal
caregiver, or did not live in the catchment area of the community
nursing organization. This may reduce the potential for the early
assisted discharge treatment, but it is still considerable, given the
size of the patient population.
This study has shown the potential impact of a detailed unit
cost calculation of an inpatient hospital day based on treatment
intensity compared with standard tariffs or references prices. A
sensitivity analysis using Dutch reference costs, which represent
average costs of a hospital day based on all patients irrespective
of their diseases [20], led to much larger savings for early assisted
discharge. From the societal perspective, the cost increase due
to early assisted discharge disappeared almost entirely. From
the health care perspective, the finding that early assisted
discharge led to cost savings was surrounded by almost no
uncertainty.
Using standard costs of a hospital day, however, would not be
opportune in this study because only the least-costly inpatient
days were substituted by home care. Furthermore, hospital care
for patients with COPD exacerbations who meet the inclusion
and exclusion criteria of our trial is likely to be less intensive than
the hospital care for the average admitted patient.
The calculations for the costs per inpatient day were not
based on a large sample of patients, whose treatment was
actually timed and recorded. This was not feasible in this study
because of the unpredictability of hospital admissions, the
relatively small number of patients eligible for the study, and
the large number of treatment aspects that would have to be
recorded. It would have required researchers permanently
present in the hospitals for a long period of time. Instead, we
interviewed hospital care providers with much experience intreating this patient group. A standardized questionnaire was
used, in which all aspects of care on a particular day were
distinguished. Respondents were not asked to estimate the total
amount of time they spent on each patient but on an average
patient. Tan et al. [22] concluded that this method leads to a good
balance between feasibility and reliability. A problem with this
method is, however, that it does not yield measures of variability
on a patient level. This means that the uncertainty about the
costs of treatment in the hospital, which inevitably exists, was
not represented in the uncertainty around the total costs of
treatment. While this may always be the case when fixed unit
costs are used, inpatient hospital days are different. They contain
a large number of separate elements—not just capital costs, hotel
services, and overhead costs, which could be fairly similar for all
patients, but also time from several health care providers for
many different aspects of care. It is conceivable that the price of a
general practitioner consultation does not differ much across
patients because all more or less take the same amount of time,
whereas inpatient hospital days are much more different for
different patients. This may not be a problem when hospital
costs are merely a relatively infrequent element in the total costs
of care, but in the initial treatment episode for COPD exacerba-
tions the costs of inpatient hospital days are virtually the only
cost driver. Therefore, we performed sensitivity analyses assum-
ing different unit cost prices per inpatient hospital day. These
gave an indication about the range of possible cost savings and
increases.
Most of the other cost studies of hospital-at-home found
larger cost savings than we did, also from a health care perspec-
tive [3,9–14]. This may be explained by the design of our
study—early assisted discharge, not admission avoidance, which
brought a reduction of four inpatient hospital days. In some other
studies, this reduction was larger. In England, two economic
evaluations were performed. Skwarska et al. [10] calculated
savings of h876 per patient by eliminating five inpatient days
(median) in an admission avoidance program (no statistical
testing was done). In contrast, Shepperd et al. [9] found signifi-
cant cost increases (difference between medians h1176) for an
early assisted discharge scheme, in which five inpatient days
were substituted for care at home as well. The cost increases in
this study were mostly due to the large proportion of patients
who were readmitted to the hospital after having been dis-
charged early compared with usual treatment, which makes it
plausible that the health effects of treatment were better in the
usual hospital care group. Although differences were not statisti-
cally significant in their small sample, almost all health indica-
tors were in favor of usual hospital care. In a Spanish study,
significant savings of around h800 were reported, the exact
amount depending on the analysis [11,12]. In this scheme, an
average of 3.8 inpatient hospital days was substituted by 1.7
home visits and 2.3 phone calls per patient. Some patients were
discharged early, while others avoided admission completely. In
this study, even some patients who were randomized to the usual
hospital treatment did not spend a night in the hospital. In an
Australian admission avoidance study, in which community
nurses were employed instead of hospital-based staff, the sav-
ings were Aus $1696 [3]. Aimonino Ricauda et al. [14] examined an
admission avoidance program in Italy. The cost difference of US
$215 was not significant. However, the hospital-at-home scheme
contained visits by physicians and a transport home by ambu-
lance for all patients, which made the cost difference smaller. In
a nonrandomized study in the United States—all previously
mentioned studies were randomized—Frick et al. [13] found the
largest savings, US $2314 per patient.
In conclusion, transferring hospital care for a COPD exacer-
bation to the patient’s home is likely to lead to modest savings in
health care costs in The Netherlands, while there is no evidence
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 1 7 – 5 2 8528that it would be medically impossible or irresponsible for
selected patients. When the societal costs of informal care and
productivity losses are taken into account, the cost savings
decrease considerably or even turn into cost increases.
Because there is no compelling reason—from a medical or
economic point of view—to recommend either the early sup-
ported discharge treatment or usual hospital care, patients’
preferences should play an important role in deciding where he
or she is treated. If homecare is preferred, this study has shown
that the widespread network of homecare organizations in The
Netherlands, which employs community nurses, is able to meet
this preference.
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